FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136860035> ?p ?o ?g. }

• W2136860035 endingPage "1592" @default.
• W2136860035 startingPage "1585" @default.
• W2136860035 abstract "Immunotherapy is one of the attractive treatment strategies for advanced prostate cancer. The US Food and Drug Administration (FDA) previously approved the therapeutic vaccine, sipuleucel-T, which is composed of autologous antigen-presenting cells cultured with a fusion protein [prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GMCSF)]. Although sipuleucel-T has been shown to prolong the median survival of patients for 4.1 months, more robust therapeutic effects may be expected by modifying the vaccination protocol. In the present study, we aimed to develop and validate a novel vaccination strategy using multiple PAP-fused cytokines for prostate cancer treatment. Using a super gene expression (SGE) system that we previously established to amplify the production of a recombinant protein, significant amounts of PAP-fused cytokines [human GMCSF, interleukin-2 (IL2), IL4, IL7 and mouse GMCSF and IL4] were obtained. We examined the activity of the fusion proteins in vitro to validate their cytokine functions. A significant upregulation of dendritic cell differentiation from monocytes was achieved by PAP-GMCSF when used with the other PAP-fused cytokines. The PAP-fused human IL2 significantly increased the proliferation of lymphocytes, as determined by flow cytometry. We also investigated the in vivo therapeutic effects of multiple PAP-fused cytokines in a mouse prostate cancer model bearing prostate-specific antigen (PSA)- and PAP-expressing tumors. The simultaneous intraperitoneal administration of PAP-GMCSF, -IL2, -IL4 and -IL7 significantly prevented tumor induction and inhibited the tumor growth in the PAP-expressing tumors, yet not in the PSA-expressing tumors. The in vivo therapeutic effects with the multiple PAP-fused cytokines were superior to the effects of PAP-GMCSF alone. We thus demonstrated the advantages of the combined use of multiple PAP-fused cytokines including PAP-GMCSF, and propose a promising prostatic antigen-vaccination strategy to enhance the therapeutic effects." @default.
• W2136860035 created "2016-06-24" @default.
• W2136860035 creator A5001674444 @default.
• W2136860035 creator A5010413301 @default.
• W2136860035 creator A5044159483 @default.
• W2136860035 creator A5051701709 @default.
• W2136860035 creator A5055828343 @default.
• W2136860035 creator A5067411754 @default.
• W2136860035 creator A5075963647 @default.
• W2136860035 creator A5079415033 @default.
• W2136860035 creator A5084874214 @default.
• W2136860035 creator A5090189688 @default.
• W2136860035 date "2015-01-29" @default.
• W2136860035 modified "2023-10-14" @default.
• W2136860035 title "A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment" @default.
• W2136860035 cites W1499815917 @default.
• W2136860035 cites W1508614672 @default.
• W2136860035 cites W1535497156 @default.
• W2136860035 cites W1563053828 @default.
• W2136860035 cites W1965598991 @default.
• W2136860035 cites W1977696847 @default.
• W2136860035 cites W1978942158 @default.
• W2136860035 cites W1982123593 @default.
• W2136860035 cites W2007590517 @default.
• W2136860035 cites W2031836547 @default.
• W2136860035 cites W2032934787 @default.
• W2136860035 cites W2045212521 @default.
• W2136860035 cites W2046297314 @default.
• W2136860035 cites W2051972386 @default.
• W2136860035 cites W2057091891 @default.
• W2136860035 cites W2065233076 @default.
• W2136860035 cites W2070064481 @default.
• W2136860035 cites W2073879459 @default.
• W2136860035 cites W2083054031 @default.
• W2136860035 cites W2084095503 @default.
• W2136860035 cites W2099243623 @default.
• W2136860035 cites W2101789965 @default.
• W2136860035 cites W2103959341 @default.
• W2136860035 cites W2113590170 @default.
• W2136860035 cites W2117884326 @default.
• W2136860035 cites W2121290865 @default.
• W2136860035 cites W2127563925 @default.
• W2136860035 cites W2155339588 @default.
• W2136860035 cites W2158614051 @default.
• W2136860035 cites W2170001501 @default.
• W2136860035 cites W2170163120 @default.
• W2136860035 cites W2261691410 @default.
• W2136860035 cites W2343922990 @default.
• W2136860035 cites W2414738294 @default.
• W2136860035 cites W252797070 @default.
• W2136860035 doi "https://doi.org/10.3892/or.2015.3770" @default.
• W2136860035 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4358080" @default.
• W2136860035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25632844" @default.
• W2136860035 hasPublicationYear "2015" @default.
• W2136860035 type Work @default.
• W2136860035 sameAs 2136860035 @default.
• W2136860035 citedByCount "11" @default.
• W2136860035 countsByYear W21368600352016 @default.
• W2136860035 countsByYear W21368600352017 @default.
• W2136860035 countsByYear W21368600352018 @default.
• W2136860035 countsByYear W21368600352019 @default.
• W2136860035 countsByYear W21368600352020 @default.
• W2136860035 countsByYear W21368600352021 @default.
• W2136860035 countsByYear W21368600352023 @default.
• W2136860035 crossrefType "journal-article" @default.
• W2136860035 hasAuthorship W2136860035A5001674444 @default.
• W2136860035 hasAuthorship W2136860035A5010413301 @default.
• W2136860035 hasAuthorship W2136860035A5044159483 @default.
• W2136860035 hasAuthorship W2136860035A5051701709 @default.
• W2136860035 hasAuthorship W2136860035A5055828343 @default.
• W2136860035 hasAuthorship W2136860035A5067411754 @default.
• W2136860035 hasAuthorship W2136860035A5075963647 @default.
• W2136860035 hasAuthorship W2136860035A5079415033 @default.
• W2136860035 hasAuthorship W2136860035A5084874214 @default.
• W2136860035 hasAuthorship W2136860035A5090189688 @default.
• W2136860035 hasBestOaLocation W21368600351 @default.
• W2136860035 hasConcept C121608353 @default.
• W2136860035 hasConcept C126322002 @default.
• W2136860035 hasConcept C203014093 @default.
• W2136860035 hasConcept C2776235491 @default.
• W2136860035 hasConcept C2776490512 @default.
• W2136860035 hasConcept C2777478134 @default.
• W2136860035 hasConcept C2777701055 @default.
• W2136860035 hasConcept C2778690821 @default.
• W2136860035 hasConcept C2780192828 @default.
• W2136860035 hasConcept C502942594 @default.
• W2136860035 hasConcept C71924100 @default.
• W2136860035 hasConcept C8891405 @default.
• W2136860035 hasConceptScore W2136860035C121608353 @default.
• W2136860035 hasConceptScore W2136860035C126322002 @default.
• W2136860035 hasConceptScore W2136860035C203014093 @default.
• W2136860035 hasConceptScore W2136860035C2776235491 @default.
• W2136860035 hasConceptScore W2136860035C2776490512 @default.
• W2136860035 hasConceptScore W2136860035C2777478134 @default.
• W2136860035 hasConceptScore W2136860035C2777701055 @default.
• W2136860035 hasConceptScore W2136860035C2778690821 @default.
• W2136860035 hasConceptScore W2136860035C2780192828 @default.
• W2136860035 hasConceptScore W2136860035C502942594 @default.

• next